Neurocrine Biosciences (NBIX) Given Media Impact Rating of 0.16
Media coverage about Neurocrine Biosciences (NASDAQ:NBIX) has been trending somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Neurocrine Biosciences earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 46.1907788836525 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the news stories that may have impacted Accern’s rankings:
- Dimitri E. Grigoriadis Sells 71,775 Shares of Neurocrine Biosciences, Inc. (NBIX) Stock (americanbankingnews.com)
- Neurocrine Biosciences, Inc. (NBIX) Insider Sells $6,764,341.76 in Stock (americanbankingnews.com)
- Neurocrine Biosciences, Inc. to Host Earnings Call (finance.yahoo.com)
- Director of Neurocrine Biosciences Inc (NASDAQ:NBIX), Lyons Gary A, sells 5,000 shares worth $415,380 (empowerednews.net)
- Neurocrine Biosciences to Present at the Leerink Partners 7th Annual Global Healthcare Conference (finance.yahoo.com)
NBIX has been the topic of several recent research reports. Needham & Company LLC lifted their target price on Neurocrine Biosciences to $95.00 and gave the stock a “buy” rating in a report on Tuesday, January 16th. Oppenheimer set a $85.00 target price on Neurocrine Biosciences and gave the stock a “buy” rating in a report on Tuesday, December 12th. Leerink Swann reaffirmed an “outperform” rating and set a $83.00 target price (up from $72.00) on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. BidaskClub raised Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a report on Wednesday, January 31st. Finally, Barclays lifted their target price on Neurocrine Biosciences from $75.00 to $85.00 and gave the stock an “overweight” rating in a report on Thursday, November 2nd. One research analyst has rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. Neurocrine Biosciences currently has a consensus rating of “Buy” and a consensus price target of $84.13.
In other news, insider Darin Lippoldt sold 9,900 shares of Neurocrine Biosciences stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $73.05, for a total value of $723,195.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Haig P. Bozigian sold 1,625 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $79.12, for a total value of $128,570.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 347,850 shares of company stock valued at $27,337,071. Corporate insiders own 4.80% of the company’s stock.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.